PCV7: COST-UTILITY ANALYSIS OF DRUG THERAPY OPTIONS FOR INTERMITTENT CLAUDICATION  by McGhan, WF
Abstracts 97
work is needed to determine whether interventions aimed
at these patients will result in improved quality of life.
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AND RISK FACTORS IN THE SEVERE AND 
PERSISTENTLY MENTALLY ILL
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OBJECTIVE: It has been estimated that 92% of geriatric
psychiatric patients have at least 1 comorbid physical dis-
order. The baby boomers will be turning 65 by 2011 and
over 130 million people will be over 45 by 2050. The se-
vere and persistently mentally population have not been
extensively studied concerning comorbidities and physi-
cal and behavioral risk factors of cardiovascular disease.
We propose to determine the cost of treatment and prev-
alence of these comorbidities and risk factors in this pop-
ulation. METHODS: We conducted a chart review of all
adult inpatients (N  179) of a state psychiatric hospital
during July and August 2000. All subjects had a medical
history, physical exam, screening blood tests, ECG and
medical service utilization data collected. The cost of
treatment and prevalence of cardiovascular disease in our
population was compared to a control group of Medicaid
recipients matched for age and sex. RESULTS: Subject
Characteristics: 47  16 years; 113 male; 29% African
American, 10% Hispanic. Cardiovascular Disease Co-
morbidities: 40% ECG abnormalities, 15% Hyperten-
sion, 10% Diabetes, 7% Thyroid Dysfunction, 6% CAD.
Physical and Behavioral Risk Factors: 69% overweight
(BMI  25), 38% obese (BMI  30); 18% hyperlipi-
demia, 67% nicotine & 49% alcohol abuse, 35% chemi-
cally addicted. Cost of Treatment: Total cost: $2539
($2257–$2821), Cost of cardiovascular disease comor-
bidities: $3889 ($2105–$5673). CONCLUSION: 49%
had cardiovascular disease comorbidities. 62% had mul-
tiple behavioral and physical risk factors for developing
cardiovascular disease in their life time. The sample size
limits our ability to make population inferences yet an as-
sociation between severe and persistently mentally ill pa-
tients and a increased risk for cardiovascular disease ex-
ists in our group (T  8.101, df  356, P  .00001).
This association is also evident in the greater cost of
treatment $1985 ($1518–$2452) of the severe and persis-
tently mentally ill compared to the control group (T 
4.78, df  108, P  .00001).
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OBJECTIVE: Methods to develop resource costs from
administrative data remain underdeveloped. Our objec-
tive was to improve current methods of estimating daily
hospitalization cost by determining the pattern of re-
source utilization for patients hospitalized with cardio-
vascular-related diagnoses. METHODS: Using a propri-
etary cost-accounting system, we assessed the proportion
of total hospital costs for each hospital day for patients
within 10 DRGs. From these proportions, a series of
equations were developed to calculate cost for each day
of hospitalization. The dataset for this analysis included
records for 2,698 patients for FY 2000. RESULTS:
27.39% of costs occurred on Day 1 for medical DRG
127 (Heart Failure, ALOS  5). For each of the remain-
ing four days the proportion of cost was 18.15%. For
surgical DRG 112 (PTCA, ALOS  3), 65.56% of costs
occurred on Day 1 and 17% occurred on each of the re-
maining two days. The average proportion of costs for
the first day of hospitalization and for each day thereafter
for the remaining medical and surgical DRGs were 30%
and 17%, and 62% and 19%, respectively. To illustrate,
the average cost per day of a DRG 112 hospitalization
was $4,333, totaling $13,000. By using the developed
equations, the cost for the first day of hospitalization was
calculated to be $8,500. The cost for each remaining day
was $2,238.60. In this example, use of an average cost
per day overestimates the marginal cost of the last day by
approximately $2,000. CONCLUSION: Average cost
per day grossly overestimates the cost savings of reduced
length of stay, especially for surgical diagnoses. The de-
veloped methodology will more accurately reflect any
cost savings from a reduced length of stay by accounting
for the greater intensity of care during the first day of a
hospital admission.
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Peripheral artery disease manifests as intermittent claudi-
cation in over 4 million people in the US. In people older
than 60 years, intermittent claudication occurs in 5% of
men and 3% of women. OBJECTIVES: The purpose of
this study was to develop a cost-utility model to compare
cilostazol, pentoxifylline, and placebo based on pub-
lished randomized control trial data. METHODS: In the
trial, 698 patients received either cilostazol 100 mg twice
a day, pentoxifylline 400 mg 3 times a day, or placebo.
Quality of life was measured with the SF-36. Survival
was projected to be similar between the three groups
from this study of 24 weeks duration and SF-36 was con-
verted to a single utility score using the regression for-
mula published by Bosch. RESULTS: On SF-36, cilosta-
zol was significantly better on the physical components
over baseline. Pentoxifylline and placebo were not signif-
icantly different on either the physical or mental compo-
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nents over baseline. On the Bosch calculated single index,
cilostazol was better than pentoxifylline and placebo.
Pentoxifylline had a lower calculated QALY score than
cilostazol or placebo. Based on this model, cilostazol had
an incremental cost per QALY of $72,153 over placebo
and $21,294 over pentoxifylline. As expected the model
is sensitive to changes in price and utilities, and patients
who have substantial improvements in QOL scores over
baseline have better cost per QALY results. From a man-
aged care perspective with a patient co-pay of 20%, the
patient’s incremental cost of cilostazol over placebo was
$14,431 per QALY and the managed care plan cost is
$57,722 per QALY. CONCLUSION: Based on this anal-
ysis of treatments for intermittent claudication, cilostazol
had a reasonable incremental cost per QALY over pen-
toxifylline or placebo. Lower cost per QALY results can
be obtained by continuing on therapy patients who attain
higher than average gains in quality of life scores from
baseline.
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OBJECTIVE: Patient compliance is an important com-
ponent in the successful management of any disease. In
general, it is assumed that in disease states involving peri-
odic, intense pain, such as angina pectoris (AP), com-
pliance rates would be high, and unaffected by dosing
regimen. We verified this hypothesis by examining the
compliance rates of patients taking different formulations
(o.d. (200–300mg), b.d. (90–120mg) and t.d.s. (60mg))
of diltiazem (princeps) for AP. METHOD: We performed
a retrospective analysis of 3455 electronic patient records
with a diagnosis of AP and a prescription of diltiazem
(princeps) from June 1st 1997 to June 1st 1998 (Medi-
plus-IMS Health) with a one-year follow-up. The above
patient cohort was then divided into 3 subgroups accord-
ing to the different formulation taken. The two sub-
groups b.d. and t.d.s. were paired to the third one, ac-
cording to 4 criteria: age, sex, disease history and co-
morbidities. Compliance was assessed using initial pre-
scription and refill rates ((pills dispensed/daily dose)/du-
ration of therapy). RESULTS: The proportion of patients
showing “good compliance” ( 0.8) was significantly
higher for the o.d. versus b.d. (36.1% versus 25.9%, p 
0.001) and for the o.d. versus t.d.s. (36.1% versus
27.1%, p  0.008). We observed the same trend when
we compared the mean rate of compliance for the o.d.
versus b.d. (0.62 versus 0.55, p  0.0027) and for the
o.d. versus t.d.s. (0.62 versus 0.60, p  0.0121). CON-
CLUSION: Even for life threatening cardiac disease like
AP, dosing regimens have a significant effect on compli-
ance. Giving diltiazem as an o.d. formulation could sig-
nificantly improve compliance and potentially decrease
health care resources used.
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OBJECTIVE: To examine the cost of illness of Conges-
tive Heart Failure (CHF) in the Louisiana Medicaid pro-
gram. METHODS: Study design: A retrospective review
of the medical and pharmacy claims data (1999–2000) in
the Louisiana Medicaid program. We reviewed pharmacy
and medical claims data for the years 1999–2000 from
the Louisiana Medicaid program. The data were ob-
tained from Unisys, the fiscal intermediary for the Louisi-
ana Medicaid program, in a PC compatible format. We
extracted the claims for CHF patients on the basis of the
ICD-9-CM codes. A total of 13,947 patients met the
study criteria, which included at least one primary or sec-
ondary diagnosis of CHF and availability of claims data
for at least one year after the first CHF diagnosis related
claim. We reviewed all the charges incurred for a one-
year period after the initial CHF claim. RESULTS: The
total cost for CHF patients for one year was over $182
million. The majority of the patients (73.63%) were fe-
male and accounted for 70% of the total cost. The mean
age was 70 years and the largest portion of the total cost
(55%) came from those 65 years and older. Of the
13,947 patients 11,065 (79%) were hospitalized at an
average cost of $4,679 per hospitalized patient. Approxi-
mately 87% of the study population received prescription
drugs at an average cost of $2,897 per prescription drug
user. Hospitalizations and prescription drugs contributed
28% and 19.38% respectively to the total cost. Almost
one third of the total cost was due to long-term care at
$13,817 per utilizer. Costs for CHF diagnosis related
claims were 14% of all costs. CONCLUSION: CHF rep-
resents a significant financial burden from the perspective
of the Louisiana Medicaid program. Improved manage-
ment of the condition is needed to reduce the cost of
treatment associated with CHF.
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Recent evidence suggests there is an increased risk of
rhabdomyolysis in patients initiated on cerivastatin com-
pared to patients initiated on other HMG CoA reductase
